Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-10-05. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Follow-Up Questions
Neurizon Therapeutics Ltd의 CEO는 누구입니까?
Dr. Michael Thurn은 2023부터 회사에 합류한 Neurizon Therapeutics Ltd의 Chief Executive Officer입니다.
NUZTF 주식의 가격 성능은 어떻습니까?
NUZTF의 현재 가격은 $0.0686이며, 전 거래일에 decreased 0% 하였습니다.
Neurizon Therapeutics Ltd의 주요 사업 주제나 업종은 무엇입니까?
Neurizon Therapeutics Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Neurizon Therapeutics Ltd의 시가총액은 얼마입니까?
Neurizon Therapeutics Ltd의 현재 시가총액은 $36.6M입니다
Neurizon Therapeutics Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Neurizon Therapeutics Ltd에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
